Boehringer Ingelheim Pharmaceuticals Inc. V. Usv Private Limited - 1:25-cv-00862

Boehringer Ingelheim Pharmaceuticals Inc. V. Usv Private Limited (Case No. 1:25-cv-00862), filed on Jul 10, 2025 in the District Court, D. Delaware involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:25-cv-00862
Filing Date
Jul 10, 2025
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. Delaware
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Boehringer Ingelheim Pharma GmbH & Co. KG -
USV Private Limited -

Patents Involved

This case involves 4 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US8551957B2
-US11090323B2
-US11833166B2
-US12115179B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Jul 10, 2025Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (scs) (Entered: 07/11/2025)PACER Document
Jul 10, 2025COMPLAINT for Patent Infringement filed against USV Private Limited (Filing fee $ 405, receipt number ADEDC-4731290) - filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG. (Attachments: # 1 Exhibits A-D, # 2 Civil Cover Sheet)(scs) (Entered: 07/11/2025)PACER Document
Jul 11, 2025Summons Issued as to USV Private Limited on 7/11/2025. (scs) (Entered: 07/11/2025)PACER Document
Jul 10, 2025Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, and Boehringer Ingelheim Pharmaceuticals Inc., filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (scs) (Entered: 07/11/2025)PACER Document
Jul 10, 2025Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,551,957 B2; 11,090,323 B2; 11,833,166 B2; 12,115,179 B2. (scs) (Entered: 07/11/2025)PACER Document
Jul 10, 2025Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: May 30, 2025. Date of Expiration of Patent(s): October 14, 2029, February 11, 2030, April 3, 2034.Thirty Month Stay Deadline: 11/30/2027. (scs) (Entered: 07/11/2025)PACER Document